Biomarkers as prognostic factors for cN2 or 3 non-small cell lung cancer treated by induction chemoradiotherapy and surgery

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1107-1116

  Yokomise, Hiroyasu ^a   Liu, Dage ^a   Chang, Sungsoo ^a   Go, Tetsuhiko ^a   Ishikawa, Sinya ^a   Misaki, Nariyuki ^a   Nakashima, Nariyasu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; ERCC1; Lung cancer biology; Lung cancer surgery; RRM1; Tubulin; TYMS

Indexed keywords

CARBOPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEMCITABINE; PEMETREXED; RIBONUCLEOTIDE REDUCTASE; ROTAXANE; THYMIDYLATE SYNTHASE; TUBULIN; UFT;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; REGRESSION ANALYSIS;

AGED; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; THYMIDYLATE SYNTHASE; TUBULIN; TUMOR SUPPRESSOR PROTEINS;

EID: 84875880646     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Martini N, Flehinger BJ, Zaman MB and Beattie EJ Jr.: Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph node metastases. Ann Surg 198: 386-397, 1983.
2. Mountain CF and Dresler CM: Regional lymph node classification for lung cancer staging. Chest 111: 1718-1723, 1997.
3. Uy KL, Darling G, Xu W, Yi QL, De Perrot M, Pierre AF, Waddell TK, Johnston MR, Bezjak A, Shepherd FA and Keshavjee S: Improved results of induction chemoradiation before surgical intervention for selected patients with stage IIIAN2 non-small cell lung cancer. J Thorac Cardiovasc Surg 134: 188-193, 2007.
4. Cerfolio RJ, Bryant AS, Jones VL and Cerfolio RM: Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg 35: 718-723, 2009.
5. Yokomise H, Gotoh M, Okamoto T, Yamamoto Y, Ishikawa S, Nakashima T, Masuya D, Liu D and Huang CL: Induction chemoradiotherapy (carboplatin-taxane and concurrent 50-Gy radiation) for bulky cN2, N3 non-small cell lung cancer. J Thorac Cardiovasc Surg 133: 1179-1185, 2007.
6. Seve P, Mackey J, Isaac S, Tredan O, Souquet PJ, Perol M, Lai R, Voloch A and Dumontet C: Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 4: 2001-2007, 2005.
7. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T and Soria JC: DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
8. Haung C, Kodama K, Liu D, Ueno M, Nakashima N, Ihikawa S, Gotoh M, Misaki N, Chang S-S and Yokomise H: Expression of ERCC1 and class III β-tubulin is associated with the survival of resected stage III non-small cell lung cancer patients treated with induction chemoradiotherapy using carboplatin-taxane. Exp Ther Med 1: 445-451, 2010.
9. Sun JM, Han J, Ahn JS, Park K and Ahn MJ: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol 6: 1392-1399, 2011.
10. Rosell R, Danenberg KD, Alberola V, Bepler G, Sanchez JJ, Camps C, Provencio M, Isla D, Taron M, Diz P and Artal A: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 10: 1318-1325, 2004.
11. Nakano J, Huang C, Liu D, Masuya D, Nakashima T, Yokomise H, Ueno M, Wada H and Fukushima M: Evaluations of biomarkers associated with 5-FU sensitivity for non-small cell lung cancer patients postoperatively treated with UFT. Br J Cancer 95: 607-615, 2006.
12. Cerfolio RJ, Ojha B, Mukherjee S, Pask AH, Bass CS and Katholi CR: Positron emission tomography scanning with 2- fluoro-2-deoxy-D-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma. J Thorac Cardiovasc Surg 125: 938-944, 2003.
13. Rami-Porta R, Mateu-Navarro M, Serra-Mitjans M and Hernandez-Rodriguez H: Remediastinoscopy: Comments and updated results. Lung Cancer 42: 363-364, 2003.
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
15. Society TJLC: Rules for Clinical and Pathological Records of Lung Cancer. 6th edition. Kanehara, Tokyo, pp.168-169, 2003.
16. Huang CL, Yokomise H, Kobayashi S, Fukushima M, Hitomi S and Wada H: Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 17: 47-54, 2000.
17. Robinson LA, Ruckdeschel JC, Wagner H Jr. and Stevens CW: Treatment of non-small cell lung cancer stage IIIA: ACCP Evidence-based Clinical Practice Guidelines (2nd edition). Chest 132: 243S-65S, 2007.
18. Albain KS, Swann RS, Rusch VW, Turrisi AT, 3rd, Shepherd FA, Smith C, Chen Y, Livingston RB, Feins RH, Gandara DR, Fry WA, Darling G, Johnson DH, Green MR, Miller RC, Ley J, Sause WT and Cox JD: Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small cell lung cancer: A phase III randomised controlled trial. Lancet 374: 379-386, 2009.
19. Soltanian S and Matin MM: Cancer stem cells and cancer therapy. Tumour Biol 32: 425-440, 2011.
20. Eramo A, Haas TL and De Maria R: Lung cancer stem cells: Tools and targets to fight lung cancer. Oncogene 29: 4625-435, 2010.
21. Yasufuku K, Pierre A, Darling G, de Perrot M, Waddell T, Johnston M, da Cunha Santos G, Geddie W, Boerner S, Le LW and Keshavjee S: A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. J Thorac Cardiovasc Surg 142: 1393-1400, 2011.
22. Cerfolio RJ, Bryant AS and Ojha B: Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study. J Thorac Cardiovasc Surg 131: 1229-1235, 2006.
23. Kaneko C, Kobayashi TK, Hasegawa K, Udagawa Y and Iwai M: A cell-block preparation using glucomannan extracted from Amorphophallus konjac. Diagn Ctyopathol 38: 652-656, 2010.